Literature DB >> 18950618

Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.

Edward D Levin1, Susan Slade, Michael Johnson, Ann Petro, Kofi Horton, Paul Williams, Amir H Rezvani, Jed E Rose.   

Abstract

Nicotine intake constitutes a principal mechanism for tobacco addiction. In addition to primary effects on nicotinic acetylcholine receptors, nicotine has cascading effects, which may also underlie its neurobehavioral actions. Nicotine induces serotonin (5-HT) release, which has not classically been thought to be involved in tobacco addiction as dopamine has. However, addiction can be characterized more as a disorder of compulsion than a disorder of enjoyment. 5-HT mechanisms play key roles in compulsive disorders. Nicotine-induced 5-HT release may be a key to tobacco addiction. Ketanserin, a 5-HT2a and 5-HT2c receptor antagonist, significantly attenuates nicotine effects on attention and memory. These studies were conducted to determine if ketanserin would reduce nicotine self-administration in rats. Male Sprague-Dawley rats (N=12) were given initial food pellet training and then 10 sessions of nicotine self-administration training (0.03 mg/kg/infusion, i.v.). Then the rats were administered ketanserin (1 or 2 mg/kg, s.c.) or the saline vehicle. Ketanserin (2 mg/kg) significantly decreased nicotine self-administration. This did not seem to be due to sedative or amnestic effects of ketanserin. In a second study, the effects of repeated administration of 2 mg/kg ketanserin (N=11) vs. saline injections (N=10) were examined. In the initial phase, the acute effectiveness of ketanserin in significantly reducing nicotine self-administration was replicated. The effect became attenuated during the following several sessions, but the significant effect became re-established during the final phases of this two-week study. 5-HT mechanisms play critical roles in the maintenance of nicotine self-administration. Better understanding of those roles may help lead to new 5-HT-based treatments for tobacco addiction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950618      PMCID: PMC2638587          DOI: 10.1016/j.ejphar.2008.10.016

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  35 in total

Review 1.  Role of dopamine in the behavioural actions of nicotine related to addiction.

Authors:  G Di Chiara
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

Review 2.  Role of serotonin(2C) receptors in the control of brain dopaminergic function.

Authors:  Vincenzo Di Matteo; Marisa Cacchio; Camillo Di Giulio; Ennio Esposito
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

3.  Involvement of serotonin in nicotine dependence: processes relevant to positive and negative regulation of drug intake.

Authors:  Peter Olausson; Jörgen A Engel; Bo Söderpalm
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

4.  Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743.

Authors:  K Varnäs; H Hall; P Bonaventure; G Sedvall
Journal:  Brain Res       Date:  2001-10-05       Impact factor: 3.252

5.  Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.

Authors:  A J Grottick; W A Corrigall; G A Higgins
Journal:  Psychopharmacology (Berl)       Date:  2001-09       Impact factor: 4.530

Review 6.  Cellular and synaptic mechanisms of nicotine addiction.

Authors:  Huibert D Mansvelder; Daniel S McGehee
Journal:  J Neurobiol       Date:  2002-12

Review 7.  Nicotinic--serotonergic interactions in brain and behaviour.

Authors:  Pallab Seth; Survjit Cheeta; Sonia Tucci; Sandra E File
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

8.  On the role of serotonin2A/2C receptors in the sensitization to cocaine.

Authors:  M Filip; E Nowak; I Papla
Journal:  J Physiol Pharmacol       Date:  2001-09       Impact factor: 3.011

Review 9.  Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics.

Authors:  Marina R Picciotto; William A Corrigall
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

Review 10.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

View more
  23 in total

1.  Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.

Authors:  Edward D Levin; Joshua E Johnson; Susan Slade; Corinne Wells; Marty Cauley; Ann Petro; Jed E Rose
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

2.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

3.  IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs.

Authors:  Vanessa Cousins; Jed E Rose; Edward D Levin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-06-20       Impact factor: 5.067

Review 4.  Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.

Authors:  Jack E Henningfield; Tracy T Smith; Bethea A Kleykamp; Reginald V Fant; Eric C Donny
Journal:  Psychopharmacology (Berl)       Date:  2016-10-21       Impact factor: 4.530

5.  Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies.

Authors:  Stevan Pecic; Pooja Makkar; Sandeep Chaudhary; Boojala V Reddy; Hernan A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2010-06-20       Impact factor: 3.641

6.  Differential effects of 5-HT(2A) and 5-HT(2C) receptor blockade on strategy-switching.

Authors:  Phillip M Baker; Jennifer L Thompson; John A Sweeney; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2011-01-12       Impact factor: 3.332

7.  Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.

Authors:  Edward D Levin; Corinne Wells; Joshua E Johnson; Amir H Rezvani; Frank P Bymaster; Jed E Rose
Journal:  Eur J Pharmacol       Date:  2015-06-20       Impact factor: 4.432

8.  Serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions in both European American and African American smokers.

Authors:  Zhongli Yang; Chamindi Seneviratne; Shaolin Wang; Jennie Z Ma; Thomas J Payne; Jundong Wang; Ming D Li
Journal:  Drug Alcohol Depend       Date:  2013-01-04       Impact factor: 4.492

9.  5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen.

Authors:  Lara A Pockros; Nathan S Pentkowski; Sineadh M Conway; Teresa E Ullman; Kimberly R Zwick; Janet L Neisewander
Journal:  Synapse       Date:  2012-09-11       Impact factor: 2.562

10.  Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.

Authors:  Maryka Quik; Archana Mallela; Matthew Chin; J Michael McIntosh; Xiomara A Perez; Tanuja Bordia
Journal:  Neurobiol Dis       Date:  2012-09-23       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.